豐原藥業(000153.SZ):已完成誠信藥業28.41%股權的交割、登記過户等工作
格隆匯 12 月 8日丨豐原藥業(000153.SZ)公佈,2020年12月1日,公司召開第八屆董事會第十一次會議,審議通過《關於轉讓江蘇誠信藥業有限公司28.41%股權的議案》。公司董事會同意公司與廈門金達威集團股份有限公司(“金達威”)、江蘇誠信藥業有限公司(“標的公司”或“誠信藥業”)及自然人喻紅忠簽署《關於江蘇誠信藥業有限公司之股權轉讓協議》。股權轉讓協議約定:金達威以1億元購買公司所持誠信藥業28.41%的股權;公司2018年7月對誠信藥業1億元投資的投資收益按原增資協議的約定由誠信藥業承擔(投資期限計算至本次股權轉讓協議生效日)。
近日,金達威已根據股權轉讓協議的約定向公司支付了此次股權轉讓款1億元。截至公告披露日,誠信藥業根據原增資協議及本次股權轉讓協議的約定向公司支付(包括以前年度已支付)投資收益款共計1746.65萬元(其中2020年度投資收益款為734.43萬元)。根據股權轉讓協議約定,公司近日已完成持有誠信藥業28.41%股權的交割、登記過户等相關工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.